HHS proposal would expand clinical trial data disclosure requirements

 

The Department of Health & Human Services has released a proposed rule that would require companies to report summary results for drugs and devices that are never approved and not just for products that reach the marketplace, reports the American Association for the Advancement of Science.

The proposed regulation would ensure that summary results for drugs that fail in trials or dropped for other reasons are made public in ClinicalTrials.gov.

Read more below:

 

 

Trimed Popup
Trimed Popup